Lysine-specific Demethylase 1 As a Therapeutic Cancer Target: Observations from Preclinical Study

Overview

Journal Expert Opin Ther Targets

Publisher Informa Healthcare

Specialty Pharmacology

Date 2023 Nov 24

PMID 37997756

Authors

Jessica D Johnson

Salvador Alejo

Sridharan Jayamohan

Gangadhara R Sareddy

Affiliations

Soon will be listed here.

Abstract

Introduction: Lysine-specific histone demethylase 1A (KDM1A/LSD1) has emerged as an important therapeutic target in various cancer types. LSD1 regulates a wide range of biological processes that influence cancer development, progression, metastasis, and therapy resistance. However, recent studies have revealed novel aspects of LSD1 biology, shedding light on its involvement in immunogenicity, antitumor immunity, and DNA damage response. These emerging findings have the potential to be leveraged in the design of effective LSD1-targeted therapies.

Areas Covered: This paper discusses the latest developments in the field of LSD1 biology, focusing on its role in regulating immunogenicity, antitumor immunity, and DNA damage response mechanisms. The newfound understanding of these mechanisms has opened possibilities for the development of novel LSD1-targeted therapies for cancer treatment. Additionally, the paper provides an overview of LSD1 inhibitor-based combination therapies for the treatment of cancer.

Expert Opinion: Exploiting LSD1 role in antitumor immunity and DNA damage response provides cues to not only understand the LSD1-resistant mechanisms but also rationally design new combination therapies that are more efficient and less toxic than monotherapy. The exploration of LSD1 biology and the development of LSD1-targeted therapies hold great promise for the future of cancer treatment.

Citing Articles

KDM1A epigenetically enhances RAD51 expression to suppress the STING-associated anti-tumor immunity in esophageal squamous cell carcinoma.

Yang Q, Wei S, Qiu C, Han C, Du Z, Wu N Cell Death Dis. 2024; 15(12):882.

PMID: 39638799 PMC: 11621790. DOI: 10.1038/s41419-024-07275-4.

[Advances in Targeted Therapy for Malignant Pleural Mesothelioma].

Fu F, Zhang Y, Shen H Zhongguo Fei Ai Za Zhi. 2024; 27(5):391-398.

PMID: 38880927 PMC: 11183316. DOI: 10.3779/j.issn.1009-3419.2024.102.18.

The Role of Amino Acids in Non-Enzymatic Antioxidant Mechanisms in Cancer: A Review.

Dyachenko E, Belskaya L Metabolites. 2024; 14(1).

PMID: 38248831 PMC: 10818545. DOI: 10.3390/metabo14010028.

References

Zhang X, Wang X, Wu T, Yin W, Yan J, Sun Y . Therapeutic potential of targeting LSD1/ KDM1A in cancers. Pharmacol Res. 2021; 175:105958. DOI: 10.1016/j.phrs.2021.105958. View

Perillo B, Ombra M, Bertoni A, Cuozzo C, Sacchetti S, Sasso A . DNA oxidation as triggered by H3K9me2 demethylation drives estrogen-induced gene expression. Science. 2008; 319(5860):202-6. DOI: 10.1126/science.1147674. View

Hosseini A, Minucci S . A comprehensive review of lysine-specific demethylase 1 and its roles in cancer. Epigenomics. 2017; 9(8):1123-1142. DOI: 10.2217/epi-2017-0022. View

Lu Y, Wajapeyee N, Turker M, Glazer P . Silencing of the DNA mismatch repair gene MLH1 induced by hypoxic stress in a pathway dependent on the histone demethylase LSD1. Cell Rep. 2014; 8(2):501-13. PMC: 4111985. DOI: 10.1016/j.celrep.2014.06.035. View

Ji X, Guo D, Ma J, Yin M, Yu Y, Liu C . Epigenetic Remodeling Hydrogel Patches for Multidrug-Resistant Triple-Negative Breast Cancer. Adv Mater. 2021; 33(18):e2100949. DOI: 10.1002/adma.202100949. View

Sheng W, LaFleur M, Nguyen T, Chen S, Chakravarthy A, Conway J . LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade. Cell. 2018; 174(3):549-563.e19. PMC: 6063761. DOI: 10.1016/j.cell.2018.05.052. View

Gajendran C, Tantry S, M N, Mohammed Z, Dewang P, Hallur M . Novel dual LSD1/HDAC6 inhibitor for the treatment of cancer. PLoS One. 2023; 18(1):e0279063. PMC: 9810167. DOI: 10.1371/journal.pone.0279063. View

Han Y, Xu S, Ye W, Wang Y, Zhang X, Deng J . Targeting LSD1 suppresses stem cell-like properties and sensitizes head and neck squamous cell carcinoma to PD-1 blockade. Cell Death Dis. 2021; 12(11):993. PMC: 8542042. DOI: 10.1038/s41419-021-04297-0. View

Alejo S, Palacios B, Pitta Venkata P, He Y, Li W, Johnson J . Lysine-specific histone demethylase 1A (KDM1A/LSD1) inhibition attenuates DNA double-strand break repair and augments the efficacy of temozolomide in glioblastoma. Neuro Oncol. 2023; 25(7):1249-1261. PMC: 10326496. DOI: 10.1093/neuonc/noad018. View

10.

Sang N, Zhong X, Gou K, Liu H, Xu J, Zhou Y . Pharmacological inhibition of LSD1 suppresses growth of hepatocellular carcinoma by inducing GADD45B. MedComm (2020). 2023; 4(3):e269. PMC: 10209615. DOI: 10.1002/mco2.269. View

11.

Cheng W, Li H, Xi S, Zhang X, Zhu Y, Xing L . Growth differentiation factor 1-induced tumour plasticity provides a therapeutic window for immunotherapy in hepatocellular carcinoma. Nat Commun. 2021; 12(1):7142. PMC: 8654996. DOI: 10.1038/s41467-021-27525-9. View

12.

Sacca C, Gorini F, Ambrosio S, Amente S, Faicchia D, Matarese G . Inhibition of lysine-specific demethylase LSD1 induces senescence in Glioblastoma cells through a HIF-1α-dependent pathway. Biochim Biophys Acta Gene Regul Mech. 2019; 1862(5):535-546. DOI: 10.1016/j.bbagrm.2019.03.004. View

13.

Alhousami T, Diny M, Ali F, Shin J, Kumar G, Kumar V . Inhibition of LSD1 Attenuates Oral Cancer Development and Promotes Therapeutic Efficacy of Immune Checkpoint Blockade and YAP/TAZ Inhibition. Mol Cancer Res. 2022; 20(5):712-721. PMC: 9081163. DOI: 10.1158/1541-7786.MCR-21-0310. View

14.

Perillo B, Tramontano A, Pezone A, Migliaccio A . LSD1: more than demethylation of histone lysine residues. Exp Mol Med. 2020; 52(12):1936-1947. PMC: 8080763. DOI: 10.1038/s12276-020-00542-2. View

15.

Pitta Venkata P, Chen Y, Alejo S, He Y, Palacios B, Loeffel I . KDM1A inhibition augments the efficacy of rapamycin for the treatment of endometrial cancer. Cancer Lett. 2021; 524:219-231. PMC: 10000284. DOI: 10.1016/j.canlet.2021.10.019. View

16.

Huang M, Chen C, Geng J, Han D, Wang T, Xie T . Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma. Cancer Lett. 2017; 398:12-21. DOI: 10.1016/j.canlet.2017.03.038. View

17.

Peng W, Zhang H, Tan S, Li Y, Zhou Y, Wang L . Synergistic antitumor effect of 5-fluorouracil with the novel LSD1 inhibitor ZY0511 in colorectal cancer. Ther Adv Med Oncol. 2020; 12:1758835920937428. PMC: 7378962. DOI: 10.1177/1758835920937428. View

18.

Greer E, Shi Y . Histone methylation: a dynamic mark in health, disease and inheritance. Nat Rev Genet. 2012; 13(5):343-57. PMC: 4073795. DOI: 10.1038/nrg3173. View

19.

Maiques-Diaz A, Spencer G, Lynch J, Ciceri F, Williams E, Amaral F . Enhancer Activation by Pharmacologic Displacement of LSD1 from GFI1 Induces Differentiation in Acute Myeloid Leukemia. Cell Rep. 2018; 22(13):3641-3659. PMC: 5896174. DOI: 10.1016/j.celrep.2018.03.012. View

20.

Cao C, Wu H, Vasilatos S, Chandran U, Qin Y, Wan Y . HDAC5-LSD1 axis regulates antineoplastic effect of natural HDAC inhibitor sulforaphane in human breast cancer cells. Int J Cancer. 2018; 143(6):1388-1401. PMC: 6105499. DOI: 10.1002/ijc.31419. View